Non-Hodgkin Lymphoma
Stay up to date on practice-changing data in community practice.
Positive Outcomes Confirmed for Frontline ICI Use in Metastatic CRC
Patients with metastatic colorectal cancer who received frontline immune checkpoint inhibitor therapy had positive OS rates and durable responses vs chemotherapy alone.
Read More
Exploring Innovations in Lymphoma Treatment With Russler-Germain
David A. Russler-Germain, MD, PhD, discusses his path in oncology and the many advancements shaping lymphoma treatment today.
Listen
FDA Oks Penpulimab for First-Line Non-Keratinizing Nasopharyngeal Carcinoma
The FDA has approved penpulimab with chemotherapy for first-line recurrent/metastatic non-keratinizing nasopharyngeal carcinoma and alone after prior treatment.
Cancer Research Across Continents: Fujiwara’s Path From Japan to the US
In this episode of Emerging Experts, Yu Fujiwara, MD, shares his journey from Japan to the United States and his path to becoming a specialist in hematology and oncology.
SUNLIGHT Trial Defines CRC in the Refractory Setting
Before the emergence of data from the SUNLIGHT trial, there were only 2 options for therapy in advanced colorectal cancer: trifluridine/tipiracil and regorafenib.
Examining Impact of Crossover in the TRANSFORM Study of CAR T in LBCL
During a live event, Nathan M. Denlinger, DO, MS, discussed the TRANSFORM trial of lisocabtagene maraleucel in B-cell lymphoma and its crossover design.
